Repeated immune activation with low-dose lipopolysaccharide attenuates the severity of Huntington's disease in R6/2 transgenic mice

SW Lee, HJ Park, W Im, M Kim, S Hong - Animal cells and systems, 2018 - Taylor & Francis
Huntington's disease (HD) is a neurodegenerative disorder caused by a mutation in the
huntingtin gene. Previously, therapeutic approaches using anti-inflammatory agents were …

[HTML][HTML] iNKT cell activation exacerbates the development of Huntington's disease in R6/2 transgenic mice

HJ Park, SW Lee, W Im, M Kim, L Van Kaer… - Mediators of …, 2019 - hindawi.com
Huntington's disease (HD) is an inherited neurodegenerative disorder which is caused by a
mutation of the huntingtin (HTT) gene. Although the pathogenesis of HD has been …

A novel Huntington's disease mouse model to assess the role of neuroinflammation on disease progression and to develop human cell therapies

H Dahlenburg, D Cameron, S Yang… - Stem cells …, 2021 - academic.oup.com
Huntington's disease (HD) is a fatal autosomal-dominant neurodegenerative disease
caused by a trinucleotide CAG repeat expansion of the huntingtin gene (HTT) that affects 1 …

Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment

J Pido-Lopez, B Tanudjojo, S Farag, MK Bondulich… - Scientific Reports, 2019 - nature.com
Huntington's disease (HD) is an inherited neurodegenerative disorder caused by the
expansion of the CAG repeat in exon 1 of the huntingtin (HTT) gene, which results in a …

Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease

HY Hsiao, FL Chiu, CM Chen, YR Wu… - Human molecular …, 2014 - academic.oup.com
Neuroinflammation is a common feature of many neurodegenerative diseases, including
Huntington's disease (HD). HD is an autosomal dominant genetic disease caused by an …

[HTML][HTML] Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models

U Träger, R Andre, A Magnusson-Lind, JRC Miller… - Neurobiology of …, 2015 - Elsevier
Inflammation is a growing area of research in neurodegeneration. In Huntington's disease
(HD), a fatal inherited neurodegenerative disease caused by a CAG-repeat expansion in the …

[PDF][PDF] Deficiency of Toll-like receptors 2, 3 or 4 extends life expectancy in Huntington's disease mice

K Griffioen, MP Mattson, E Okun - Heliyon, 2018 - cell.com
Abstract Huntington's disease (HD), an autosomal dominant neurodegenerative disorder
characterized by progressive striatal and cortical atrophy, has been strongly linked with …

[HTML][HTML] Neuroinflammation in Huntington's disease: From animal models to clinical therapeutics

Q Jia, S Li, XJ Li, P Yin - Frontiers in Immunology, 2022 - frontiersin.org
Huntington's disease (HD) is a progressive neurodegenerative disease characterized by
preferential loss of neurons in the striatum in patients, which leads to motor and cognitive …

Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant …

S Liu, X Yu, J Zhu, X Liu, Y Zhang, Q Dong, S Ma, R Liu - Brain Research, 2018 - Elsevier
Huntington's disease (HD) is a fatal neurodegenerative disorder characterized by
progressive movement disorders and cognitive deficits, which is caused by a CAG-repeat …

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

M Björkqvist, EJ Wild, J Thiele, A Silvestroni… - The Journal of …, 2008 - rupress.org
Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by both
neurological and systemic abnormalities. We examined the peripheral immune system and …